Project Grant R21AI196275
- Federal Grant Award Summary Duke University's Office of Research Administration received a $597,613 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026, through March 31, 2031. This R01 grant supports investigator-initiated research developing ex vivo delivery of adeno-associated virus (AAV) vector-mediated gene therapy to genetically modify donor lung grafts...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $444,125 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2027. The award supports investigator-initiated biomedical research focused on developing and evaluating therapeutic interventions for xenotransplantation rejection. Specifically, the...
- Federal Grant Award Summary Duke University received a $3.19M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 21, 2025, with a completion date of July 31, 2029. The grant supports research addressing immunomodulation in adeno-associated virus (AAV) gene therapy, a critical challenge in the treatment of monogenic disorders. AAV-based gene therapies are advancing clinically...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $161,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with a completion date of March 31, 2028. The grant funds the development of new genetic tools—specifically Cre (Cre/CreERT2) mouse models—designed to enable selective targeting and lineage tracing of plasma...
- Federal Grant Award Summary Duke University's Office of Research Administration received a Project Grant award of $127,527 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective November 1, 2025, with a completion date of April 30, 2028. The award supports investigator-initiated biomedical research focused on defining the role of the RGS12 locus in macrophage function, specifically examining how...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.1 million Project Grant to the University of California, Los Angeles under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This award funds research to evaluate the mechanisms underlying immunosuppression induction and maintenance impacts on T cell function following kidney transplantation. The research employs...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Harvard College's Office for Sponsored Programs a $916,436 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 5, 2026, with a completion date of January 31, 2031. This award supports research in human thymus engineering aimed at developing scalable methods for producing functional, antigen-specific T cells derived from induced pluripotent...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on novel immunotherapeutic approaches for Type 1 Diabetes. The award, effective April 1, 2026 through March 31, 2028, funds an investigator-initiated research project titled "Coreceptor Therapy-Induced...
- Federal Grant Award Summary Duke University's Office of Research Administration was awarded $449,408 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period from July 1, 2025 through June 30, 2027. The project focuses on developing diagnostic antibodies for acute and chronic Chagas disease, a neglected tropical disease caused by infection with the parasite Trypanosoma cruzi. The...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 13, 2026, with completion scheduled for January 31, 2028. This research initiative focuses on identifying prognostic biomarkers in invasive candidiasis by developing and validating host gene expression signatures that can...
Grant Award Summary Duke University's Office of Research Administration received a $444,125 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2028. This award funds research designed to accelerate immune reconstitution following cultured thymus tissue implantation (CTTI), also referred to as thymus transplantation. The research team will identify and manipulate regulatory pathways that control thymus growth and maturation using murine models, employing two distinct intervention approaches: ex vivo gene therapy utilizing adeno-associated virus vectors and pharmaceutical interventions. The project will evaluate the impacts of these manipulations on implanted thymus growth, the speed of immune reconstitution, and the quality of T cell recovery following CTTI. The research addresses a critical clinical need to prevent infection-related mortality occurring during the immune reconstitution period following CTTI, thereby enabling broader application of this tolerance-inducing transplantation method. Building on the research team's prior success in human CTTI/heart co-transplantation and established expertise in thymus biology and gene therapy, the deliverables from this grant include preclinical data demonstrating enhanced T cell reconstitution rates and thymus functionality. The translatable findings from this work have potential applicability beyond transplantation, including accelerating T cell recovery following cancer treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $444.1k | 3/27/26 |